A Molecular Genetic Registry as a Tool for Personalized Treatment of Non-small Cell Lung Cancer

Background : Given the rising incidence of cancer, particularly lung cancer, along with advancements in molecular genetic research, there is an increasing need to implement modern diagnostic approaches based on the assessment of molecular alterations. The study of molecular genetic changes in lung cancer is a critical step toward the timely initiation of targeted therapies and the prediction of disease progression. The establishment of molecular genetic study registry will enable the systematic collection and analysis of data on the genomics of non-small cell lung cancer (NSCLC), tumor histology, disease stages, and treatment strategies. Furthermore, such a registry will enhance accurate epidemiological analyses and, in the future, support the identification of cancer distribution patterns as well as monitoring of treatment outcomes. Objective : Сreation of a registry for molecular-genetic data for personalized treatment of lung cancer. Materials and methods : An analysis of 128 clinical cases diagnosed with NSCLC was conducted using Next–Generation Sequencing (NGS) on the MiSeqDX platform (Illumina, USA) in accordance with the manufacturer’s instructions. Results : In the course of the study, the obtained results, including genetic data, were systematically organized in a registry, on the basis of which both population characteristics and individual patient data were generated. The most frequently identified mutations were in the KRAS and EGFR genes: 28% and 19%, respectively. Some patients were found to have rare mutations in ALK (2%), BRAF (1%), RET (2%), which may require specific targeted therapies. Among the 128 patients, 49 cases of various co-mutations were identified, which may affect treatment resistance and disease progression. Сonclusion : The implementation of a molecular genetic research registry has enabled a comprehensive analysis of population characteristics and personalized treatment strategies for individual patients.